Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APC8015F
- Development stage
- Unknown
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
APC8015F is an autologous active cellular immunotherapy developed by Dendreon for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a specific formulation of sipuleucel-T (Provenge) manufactured from cryopreserved peripheral blood mononuclear cells (PBMCs) rather than fresh cells. The manufacturing process involves activating a patient's own antigen-presenting cells (APCs) in vitro with PA2024, a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor (GM-CSF). Once infused, these activated cells are intended to stimulate a T-cell mediated immune response against prostate cancer cells expressing the PAP antigen. APC8015F was primarily utilized in crossover protocols, such as the Phase 2 trial for patients who experienced disease progression while on the placebo arm of the pivotal Phase 3 IMPACT trial.
- Other names
- frozen sipuleucel-Tcryopreserved sipuleucel-T
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on APC8015F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APC8015F.